Tybourne Capital Management logo

Tybourne Capital Management

Asia, Hong Kong Island, Hong Kong, Hong Kong

Description

Tybourne Capital Management is a distinguished global investment firm headquartered in Hong Kong, established in 2012 by Alex S.L. King. The firm operates with a core philosophy centered on fundamental research and a long-term investment horizon, deploying capital across both public and private equity markets worldwide. Their strategy is characterized by a deep dive into company fundamentals, seeking to identify and support high-quality businesses with strong growth potential and resilient business models.

With substantial assets under management, Tybourne has solidified its position as a major player in the global investment landscape. Reports from 2023 indicated their AUM to be approximately $20 billion, underscoring their capacity to make significant capital commitments. This considerable financial backing enables them to pursue large-scale opportunities across diverse sectors, including technology, consumer, healthcare, and financial services, with a particular focus on disruptive innovators and market leaders.

In the private equity domain, Tybourne Capital Management is recognized for its strategic investments in late-stage growth and pre-IPO companies. They have been active participants in major funding rounds for some of the world's most impactful technology firms, including ByteDance, the parent company of TikTok, and leading Southeast Asian super-apps like GoTo (formerly Go-Jek) and Grab. These investments highlight their preference for established, high-growth enterprises that are nearing or have achieved significant market penetration.

The firm's typical first cheque sizes for private investments are substantial, aligning with their focus on growth-stage companies that require significant capital for expansion and market dominance. While specific figures can vary based on the opportunity, Tybourne generally commits between $50 million and $300 million for initial investments. This range reflects their commitment to acquiring meaningful stakes and providing substantial support to their portfolio companies, fostering long-term partnerships with management teams dedicated to innovation and market leadership.

Investor Profile

Tybourne Capital Management has backed more than 24 startups, with 1 new investments in the last 12 months alone. The firm has led 5 rounds, about 21% of its total and boasts 8 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series B, Series D rounds (top funding stages).
  • Majority of deals are located in United States, Japan, India.
  • Strong thematic focus on Biotechnology, Pharmaceutical, Health Care.
  • Typical check size: $50M – $300M.

Stage Focus

  • Series C (33%)
  • Series B (29%)
  • Series D (13%)
  • Series A (8%)
  • Post Ipo Debt (4%)
  • Series Unknown (4%)
  • Series E (4%)
  • Post Ipo Equity (4%)

Country Focus

  • United States (33%)
  • Japan (17%)
  • India (17%)
  • China (13%)
  • South Korea (4%)
  • Switzerland (4%)
  • Vietnam (4%)
  • United Kingdom (4%)
  • Indonesia (4%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Payments
  • Software
  • Finance
  • Fintech
  • Biopharma
  • E-commerce
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Tybourne Capital Management frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 5
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 3
Farallon Capital Management
North America, California, United States, San Francisco
Co-Investments: 3
Casdin Capital
North America, New York, United States, New York
Co-Investments: 3
Alger
North America, New York, United States, New York
Co-Investments: 2
Temasek Holdings
Asia, Central Region, Singapore, Singapore
Co-Investments: 3
Marshall Wace
Europe, England, United Kingdom, London
Co-Investments: 3
Viking Global Investors
North America, Connecticut, United States, Stamford
Co-Investments: 3
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 4
Alpha Wave Global
North America, Florida, United States, Miami
Co-Investments: 3

Which angels does Tybourne Capital Management often collaborate with?

MM
Asia, Japan
Shared Deals: 1
BT
North America, Massachusetts, United States, Marblehead
Shared Deals: 1
RT
North America, Texas, United States, Houston
Shared Deals: 1

What are some of recent deals done by Tybourne Capital Management?

Forte Biosciences

Sherman Oaks, California, United States

Forte Biosciences is a biotechnology company that focuses on dermatology.

BiotechnologyHealth CareLife SciencePharmaceutical
Post Ipo EquityNov 20, 2024
Amount Raised: $53,000,000
SkyCell

Zürich, Zurich, Switzerland

SkyCell focuses on developing temperature controlled logistics containers for the pharmaceutical industry.

LogisticsPharmaceuticalSupply Chain ManagementTransportation
Series DJun 25, 2024
Amount Raised: $59,000,000
Forte Biosciences

Sherman Oaks, California, United States

Forte Biosciences is a biotechnology company that focuses on dermatology.

BiotechnologyHealth CareLife SciencePharmaceutical
Post Ipo DebtAug 1, 2023
Amount Raised: $25,000,000
Asuene

Tokyo, Tokyo, Japan

Asuene provides renewable power retail services for local production and consumption.

EnergyLocalRenewable Energy
Series BSep 14, 2022
Amount Raised: $17,491,814
ACELYRIN

Los Angeles, California, United States

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

BiopharmaBiotechnologyHealth Care
Series CSep 13, 2022
Amount Raised: $300,000,000
Kopi Kenangan

Jakarta, Jakarta Raya, Indonesia

Kopi Kenangan is Indonesia’s fastest-growing coffee chain, leveraging on a tech-based 'grab & go' strategy.

CoffeeFood and Beverage
Series CDec 27, 2021
Amount Raised: $96,000,000
Lunit

Seoul, Seoul-t'ukpyolsi, South Korea

Lunit is a medical technology company that specializes in developing and providing AI-powered medical imaging solutions.

Artificial Intelligence (AI)Computer VisionHealth DiagnosticsImage RecognitionMachine LearningMedical DeviceSoftware
Series UnknownNov 29, 2021
Amount Raised: $61,000,000
ACELYRIN

Los Angeles, California, United States

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

BiopharmaBiotechnologyHealth Care
Series BNov 16, 2021
Amount Raised: $250,000,000
CADDi

Kuramae, Tokyo, Japan

CADDi is an online ordering platform that tracks industrial products for the manufacturing business.

Information ServicesInformation TechnologyManufacturingSupply Chain Management
Series BAug 23, 2021
Amount Raised: $73,213,985
Zentera Therapeutics

Shanghai, Shanghai, China

Zentera Therapeutics is a biopharmaceutical company.

BiotechnologyPharmaceutical
Series BAug 4, 2021
Amount Raised: $75,000,000